Key regions: Australia, Japan, United States, Germany, Europe
The use of Anti-Coagulants has been on the rise in Timor-Leste, with an increasing number of patients opting for this medication to prevent blood clots.
Customer preferences: Patients in Timor-Leste are becoming more aware of the benefits of Anti-Coagulants in preventing blood clots, especially for those who have undergone surgery or have a history of heart disease. The convenience of taking a pill instead of injections is also a factor that patients consider when choosing this medication.
Trends in the market: The Anti-Coagulants market in Timor-Leste is expected to grow due to the increasing prevalence of heart diseases and the aging population. The market is also driven by the rising awareness of the benefits of Anti-Coagulants and the availability of generic versions of the medication. However, the market growth is hindered by the high cost of the medication and the limited availability of healthcare facilities in the country.
Local special circumstances: Timor-Leste is a small country with limited healthcare facilities, which affects the availability and accessibility of Anti-Coagulants. Patients may have to travel long distances to access healthcare facilities that provide this medication. Furthermore, the high cost of Anti-Coagulants may make it unaffordable for some patients.
Underlying macroeconomic factors: The economic development of Timor-Leste is still in its early stages, with a majority of the population living in rural areas and relying on subsistence farming. This limits the affordability of Anti-Coagulants for many patients. Additionally, the lack of infrastructure and investment in the healthcare sector makes it challenging to provide adequate healthcare services to the population. However, there are efforts by the government and international organizations to improve the healthcare system and increase access to medication, including Anti-Coagulants.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
